Viewing Study NCT06738966


Ignite Creation Date: 2025-12-24 @ 4:30 PM
Ignite Modification Date: 2025-12-24 @ 4:30 PM
Study NCT ID: NCT06738966
Status: RECRUITING
Last Update Posted: 2025-07-16
First Post: 2024-12-09
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Sponsor: Shanghai Best-Link Bioscience, LLC
Organization:

Study Overview

Official Title: An International, Multi-Center, Open-label Phase I Study to Evaluate the Tolerance, Pharmacokinetics, and Anti-Tumor Effects of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
Status: RECRUITING
Status Verified Date: 2025-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are:

* Does the investigational drug BL0175 is safe for participants after dosed -multiple times?
* Which is the highest safety dose of BL0175 after multiple dose?
* What medical problems do participants have when using BL0175?
* Does the investigational drug BL0175 works for participants after dosed -multiple times?
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: